Surgical Endoscopy

, Volume 24, Issue 11, pp 2913–2915

High-quality clinical practice: laparoscopic rectal cancer resection

Letter
  • 37 Downloads

References

  1. 1.
    Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801CrossRefGoogle Scholar
  2. 2.
    Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16(11):3038–3047CrossRefPubMedGoogle Scholar
  3. 3.
    Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696CrossRefPubMedGoogle Scholar
  4. 4.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefPubMedGoogle Scholar
  5. 5.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMedGoogle Scholar
  6. 6.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRefGoogle Scholar
  8. 8.
    Briasoulis E, Fatouros M, Roukos D (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695CrossRefPubMedGoogle Scholar
  9. 9.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMedGoogle Scholar
  10. 10.
    Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMedGoogle Scholar
  14. 14.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMedGoogle Scholar
  15. 15.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMedGoogle Scholar
  16. 16.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMedGoogle Scholar
  20. 20.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author’s reply 1363)CrossRefPubMedGoogle Scholar
  24. 24.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMedGoogle Scholar
  27. 27.
    Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMedGoogle Scholar
  29. 29.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMedGoogle Scholar
  30. 30.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197; author reply 198CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMedGoogle Scholar
  34. 34.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Ioannina, School of MedicineIoanninaGreece

Personalised recommendations